Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • November 2016 •
  • 61 pages •
  • Report ID: 4399386 •
  • Format: PDF
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Summary
Asthma is a chronic condition affecting the respiratory system, with disease occurrence linked to both genetic and environmental factors. It has significant global incidence and there is currently no cure. Pharmacotherapeutic intervention aims to provide patients with an increased level of disease control and reduce the severity of symptoms, and a number of inhalational therapeutic options are available.

While the asthma market is dominated almost exclusively by small molecules, which account for 99.6% of available products, the asthma pipeline consists of 13% general biologics and 12% monoclonal Antibodies (mAb). There are 173 small molecules, equating to 65%. The rise in mAb development is possibly due to the success of Xolair (omalizumab), one of the few currently marketed mAb asthma therapeutics, which reached blockbuster status in 2014. Xolair is a recombinant humanized anti-IgE, and was the first humanized therapeutic mAb to be indicated for asthma.

Over the past decade, the pharmaceutical industry has witnessed a profound change in the technological, clinical and commercial landscape across several therapeutic areas and indications. These changes include a remarkable transition towards biologic products in R&D, on an unprecedented scale. This has been facilitated by significant advances in recombinant DNA technologies, which accelerated the capabilities in the design of biologic therapeutics and substantially improved the yields in the manufacturing processes for biologics, improving productivity and profitability. As a result of these developments, the number and diversity of molecule types in developmental pipelines have increased substantially, and are expected to continue to grow in the years to come, particularly mAbs, proteins, peptides and vaccines.

The prevalence of asthma in the US increased from 7.3% in 2001 to 8.4% in 2010 (CDC, 2012). Data derived from the same study also confirmed the prevalence of asthma to be higher among children than adults, and higher among multiple-race, black, and American Indian or Alaska Native people than white people, for the 2008–2010 period.

The report “Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation” provides the following -
- Analysis of innovation in the asthma market in the context of the overall pipeline and current market landscape – also includes analysis of the deals landscape surrounding first-in-class products in asthma, and highlights opportunities for in-licensing.
- A brief introduction to asthma, including symptoms, pathophysiology, and an overview of pharmacotherapy.
- The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
- Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
- Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
- Assessment of the licensing and co-development deal landscape for asthma therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products.

Scope
- Analysis of innovation in the asthma market in the context of the overall pipeline and current market landscape – also includes analysis of the deals landscape surrounding first-in-class products in asthma, and highlights opportunities for in-licensing
- A brief introduction to asthma, including symptoms, pathophysiology, and an overview of pharmacotherapy
- The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline
- Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target
- Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets
- Assessment of the licensing and co-development deal landscape for asthma therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products

Reasons to buy
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment strategies currently available.
- Visualize the composition of the asthma market in terms of the dominant classes of therapies. Unmet needs are highlighted to allow a competitive understanding of current gaps in the market.
- Analyze the asthma pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are signs in the pipeline that the industry is seeking novel approaches to meet unmet needs within asthma.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify commercial opportunities in the asthma deals landscape by analyzing trends in licensing and co-development deals and assessing asthma therapies that are not yet involved in deals, and may be potential investment opportunities.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.